(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 September 2023 (21.09.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/177691 A1

(51) International Patent Classification:
A61K 38/17 (2006.01) *A61K 9/00* (2006.01)
A61P 27/02 (2006.01)

(21) International Application Number:
PCT/US2023/015225

(22) International Filing Date:
14 March 2023 (14.03.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/319,869	15 March 2022 (15.03.2022)	US
63/404,512	07 September 2022 (07.09.2022)	US
63/404,893	08 September 2022 (08.09.2022)	US
63/411,594	29 September 2022 (29.09.2022)	US
63/412,165	30 September 2022 (30.09.2022)	US
63/421,298	01 November 2022 (01.11.2022)	US
63/434,920	22 December 2022 (22.12.2022)	US
63/444,480	09 February 2023 (09.02.2023)	US
3190733	22 February 2023 (22.02.2023)	CA
63/447,582	22 February 2023 (22.02.2023)	US

(71) Applicants: **REGENERON PHARMACEUTICALS, INC.** [US/US]; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **BAYER HEALTHCARE LLC** [US/US]; 100 Bayer Boulevard, Whippany, New Jersey 07981 (US).

(72) Inventors: **VITTI, Robert L.**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **BERLINER, Alyson J.**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **CHU, Karen**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **ASMUS, Friedrich**; Eitel-Fritz-Str. 2, 14129 Berlin (DE). **DA SILVA LEAL, Sergio Casimiro**; In den Steinreben 6A, 4153 Reinach (CH). **EISSING, Thomas**; Kirschbaum 15, 40764 Langenfeld (DE). **RITTENHOUSE, Kay D.**; 15 Ridgewood Drive, Randolph, New Jersey 07869 (US).

(74) Agent: **TERMES, Lance A.**; Schwabe, Williamson & Wyatt PC, 1211 SW 5th Ave., Suite 1900, Portland, Oregon 97204 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,

(54) Title: EXTENDED, HIGH DOSE VEGF ANTAGONIST REGIMENS FOR TREATMENT OF ANGIOGENIC EYE DISORDERS



FIG. 1

(57) Abstract: The present invention relates to regimens for the treatment of angiogenic eye disorders such as nAMD, characterized by high doses of aflibercept and extended intervals between doses.

[Continued on next page]

WO 2023/177691 A1

HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*